AnaptysBio, Inc. to Post Q2 2022 Earnings of ($0.59) Per Share, Wedbush Forecasts (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANABGet Rating) – Research analysts at Wedbush lowered their Q2 2022 earnings per share estimates for AnaptysBio in a note issued to investors on Wednesday, May 4th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will post earnings per share of ($0.59) for the quarter, down from their prior estimate of ($0.47). Wedbush currently has a “Neutral” rating on the stock. Wedbush also issued estimates for AnaptysBio’s Q3 2022 earnings at ($1.02) EPS, Q4 2022 earnings at ($1.08) EPS, FY2022 earnings at ($4.00) EPS, FY2023 earnings at ($4.35) EPS, FY2024 earnings at ($3.39) EPS and FY2025 earnings at ($2.18) EPS.

AnaptysBio (NASDAQ:ANABGet Rating) last announced its quarterly earnings results on Wednesday, May 4th. The biotechnology company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.99) by ($0.32). AnaptysBio had a negative net margin of 143.46% and a negative return on equity of 20.44%.

Other analysts also recently issued reports about the company. Zacks Investment Research upgraded AnaptysBio from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 17th. HC Wainwright increased their price objective on shares of AnaptysBio from $43.00 to $46.00 and gave the stock a “buy” rating in a research note on Monday, March 7th. Guggenheim cut shares of AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Tuesday, March 22nd. Finally, cut AnaptysBio from a “hold” rating to a “sell” rating in a research report on Tuesday, April 26th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. Based on data from, the company currently has an average rating of “Hold” and a consensus price target of $37.25.

Shares of ANAB opened at $22.67 on Monday. AnaptysBio has a 52 week low of $20.56 and a 52 week high of $37.89. The stock has a market cap of $638.98 million, a P/E ratio of -8.24 and a beta of 0.17. The business’s 50 day moving average price is $25.52 and its 200-day moving average price is $30.02.

Large investors have recently modified their holdings of the stock. Point72 Asset Management L.P. bought a new position in shares of AnaptysBio during the 4th quarter valued at approximately $8,936,000. Laurion Capital Management LP purchased a new position in AnaptysBio in the fourth quarter worth about $6,081,000. Great Point Partners LLC increased its stake in AnaptysBio by 37.4% during the third quarter. Great Point Partners LLC now owns 549,545 shares of the biotechnology company’s stock worth $14,904,000 after acquiring an additional 149,494 shares during the last quarter. Eversept Partners LP raised its position in AnaptysBio by 134.0% during the fourth quarter. Eversept Partners LP now owns 182,612 shares of the biotechnology company’s stock valued at $6,346,000 after purchasing an additional 104,558 shares during the period. Finally, Walleye Capital LLC bought a new stake in shares of AnaptysBio in the 4th quarter valued at approximately $2,703,000.

AnaptysBio Company Profile (Get Rating)

AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.

Recommended Stories

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with's FREE daily email newsletter.